Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We feel great about how those conversations are going |
| In the quarter, we achieved a positive coverage decision from CMS for our proprietary transplant assay, saw significant new data release, and made progress on key manufacturing milestones |
| It's very positive |
| The ability to combine clinical innovation from our lab with our easy to use product is what will set OncoCyte up to be the market leader in global transplant patient management |
| If approved, this opens up a significant recurring revenue opportunity |
| That yes, there's strong demand out there |
| You can expect strong clinical validation followed by rapid kit development and deployment |
| And the fact that we were able to convert our lab developed test or LDT workflow into a globally distributable product speaks to the robustness of the assay and the underlying technology |
| Q3 saw much of the benefit of the cost reductions we did in the first half of the year |
| This is a 72% improvement in cash burn year-over-year |
| And we feel that we're going to be able to bring something home for the OncoCyte shareholders |
| From the IO product specifically progress continues on the 800 plus patient SWOG study in triple-negative breast cancer and assuming a positive outcome there, we expect that there will be significant strategic interest in the assay |
| The data shows using our technology gives an opportunity for earlier intervention |
| We believe that our universal PCR-based workflow is quicker and easier to use than anything built on the back of a next-generation sequencing system |
| We believe our path to revenue is clear with multiple products launching in the first half of 2024 and our plans to layer high margin products on top of a capital light infrastructure will set OncoCyte up for rapid value creation |
| And I would say the conversation took a very positive turn when we got the coverage decision and then when this data that was presented at ESOT about a month-and-a-half ago came out |
| We are pleased with the progress we are making in these discussions and expect to be able to update the market as more information becomes available in the near-term |
| By 2026, if we've hit all our development milestones, we believe that rapid local testing for transplant recipients will be the norm, and patient compliance and access to this organ saving technology will be at an all-time high |
| We expect that billions of annual margin opportunity are going to shift over the next few years to meet this growing demand |
| Single site is a process available to labs like ours to gain clearance for their products and usually has the advantage of bringing all your clinical data with it instead of needing to rerun a bunch of studies |
| Companies that do a good job of making testing accessible and easy to use are going to be the natural financial beneficiaries of this change |
| General and administrative expense for the third quarter decreased 56% year-over-year from $5.7 million to $2.5 million, reflecting our successful efforts to reduce spending |
| Our kitted product will follow a parallel path known as 510(k) that will be able to tap into the great clinical work we are doing in the lab |
| Non-GAAP operating losses adjusted for the third quarter was $4.1 million, an increase of $1.9 million compared to the same period in 2022 |
| The demand for local testing options is growing by the date |
| As of today, our progress continues to support and draw interest from strategic partners that would like to see this testing in their channel |
| Research and development expense for the third quarter increased 48% year-over-year from $1.5 million to $2.2 million, driven by our strategic pivot to focus on investment in developing manufactural versions of our assays |
| As I mentioned earlier, we believe easy to use regulated product is the future of the market is pushing us towards |
| Understand |
| While we are building out the manufactured product, we plan to continue to create clinical value through our innovation centers in Nashville and Germany |
| Statement |
|---|
| Many of them will go on to have rejection and potentially lose their organ |
| I think you said you expect to remain below $5 million quarterly average |
| GAAP net loss from continuing operations of $6.5 million, or $0.79 per share as compared to a net loss of $1.8 million, or $0.31 per share for the third quarter of 2022 |
| Those that become DSA positive are at higher risk for rejection |
| We're just waiting on data to generate at this time |
Please consider a small donation if you think this website provides you with relevant information